Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G P Bansal

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Developments in Biological Standardization|January 1, 1994
Protective immunity elicited by rBCG vaccinesC K Stover, G P Bansal, S Langerman, et al.
Developments in Biological Standardization|January 1, 1995
Efficacy and safety of live recombinant BCG vaccinesM S Hanson, G P Bansal, S Langermann, et al.
AIDS Research and Human Retroviruses|August 1, 1992
Development and analysis of recombinant BCG vector systemsT R Fuerst, V F de la Cruz, G P Bansal, et al.
European Journal of Immunology|January 1, 1995
Effect of anti-V3 antibodies on cell-free and cell-to-cell human immunodeficiency virus transmissionG Pantaleo, J F Demarest, M Vaccarezza, et al.
Cytokine|March 1, 1991
Suppression of bacterial cell wall-induced polyarthritis by recombinant gamma interferonJ B Allen, G P Bansal, G M Feldman, et al.
Advances in Experimental Medicine and Biology|January 11, 1992
Use of recombinant BCG as a vaccine delivery vehicleC K Stover, V F de la Cruz, G P Bansal, et al.
Journal of Virology|June 1, 1992
Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolatesM Robert-Guroff, K Aldrich, R Muldoon, et al.
The Journal of Infectious Diseases|May 1, 1993
Candidate recombinant vaccine for human B19 parvovirusG P Bansal, J A Hatfield, F E Dunn, et al.
The Journal of Experimental Medicine|July 1, 1993
Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccineC K Stover, G P Bansal, M S Hanson, et al.
Nature|June 6, 1991
New use of BCG for recombinant vaccinesC K Stover, V F de la Cruz, T R Fuerst, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Developments in Biological Standardization|January 1, 1994
Protective immunity elicited by rBCG vaccinesC K Stover, G P Bansal, S Langerman, et al.
Developments in Biological Standardization|January 1, 1995
Efficacy and safety of live recombinant BCG vaccinesM S Hanson, G P Bansal, S Langermann, et al.
AIDS Research and Human Retroviruses|August 1, 1992
Development and analysis of recombinant BCG vector systemsT R Fuerst, V F de la Cruz, G P Bansal, et al.
European Journal of Immunology|January 1, 1995
Effect of anti-V3 antibodies on cell-free and cell-to-cell human immunodeficiency virus transmissionG Pantaleo, J F Demarest, M Vaccarezza, et al.
Cytokine|March 1, 1991
Suppression of bacterial cell wall-induced polyarthritis by recombinant gamma interferonJ B Allen, G P Bansal, G M Feldman, et al.
Advances in Experimental Medicine and Biology|January 11, 1992
Use of recombinant BCG as a vaccine delivery vehicleC K Stover, V F de la Cruz, G P Bansal, et al.
Journal of Virology|June 1, 1992
Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolatesM Robert-Guroff, K Aldrich, R Muldoon, et al.
The Journal of Infectious Diseases|May 1, 1993
Candidate recombinant vaccine for human B19 parvovirusG P Bansal, J A Hatfield, F E Dunn, et al.
The Journal of Experimental Medicine|July 1, 1993
Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccineC K Stover, G P Bansal, M S Hanson, et al.
Nature|June 6, 1991
New use of BCG for recombinant vaccinesC K Stover, V F de la Cruz, T R Fuerst, et al.
Pageof 2